TickerTalks
Browse all tickers →
TickerTalks›$MDLN
MDMDLN

Medline Inc.

$MDLN·$30B·Medical - Instruments & Supplies·Healthcare
$35.28+1.8%YTD+0.3%1Y-14.0%
Mentions · last 7 days
2026-08-21: 5 posts2026-08-22: 9 posts2026-08-23: 19 posts56+3%
Price updated 2d ago·X counts updated 7d ago
MDMDLN
$MDLNMedline Inc.
$35.28+1.82%56 posts+3%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $MDLN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersCooling offAI verdict · as of 2026-08-30

Catching its breath after a run — could pick back up or fade from here.

Medline flat YTD, -14% TTM — Kaplan Fox securities investigation is fresh headline risk ahead of Nov 4 print.

Medline Inc. is a $29.8B medical-supplies major. Real-business at scale but a Kaplan Fox / Kessler Topaz securities investigation is the fresh overhang.

How it reads:

  • Growth is steady: Q1 revenue +10.7% YoY to $7.35B — real, mid-teens growth at scale.
  • Margins are thin: 7% operating margin, 5.4% FCF yield — the distributor economics do what they do.
  • Valuation is full: 28.5x PE, 0.98x sales, 13.2x EV/EBITDA on 5% ROIC — priced as a defensive growth story.
  • Position is weak: no 52w context, 6.6% below 50-day — quiet distribution.
  • Kaplan Fox / Kessler Topaz securities investigation announced Aug 21-28 is the specific catalyst — multiple firms circling means real class-action risk, but no complaint filed yet.
  • No X sentiment sample available — chatter is thin.
  • Insider signal is silent: zero transactions in 90-day window — no distribution to fade, no accumulation to lean on.

The Nov 4 print is the test — reiterated FY27 revenue guide plus specific commentary on the securities investigation timeline defends the multiple; an EPS miss plus expanded investigation scope drops to $32 support.

What to watch: Nov 4 earnings — reiterated FY27 revenue guide plus specific commentary on the securities investigation timeline defends the multiple; an EPS miss plus expanded investigation scope drops to $32 support.

On the calendar: 2026-11-04 — Q3 earnings

no sentiment sample52w missingvs 200d missing

Read the AI verdict + X sentiment for $MDLN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Manufactures and distributes medical-surgical supplies (gloves, gowns, IV sets) directly to hospitals, surgery centers, and post-acute facilities.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Instruments & Supplies sits in its cycle right now — and what that implies for $MDLN.

Medical - Instruments & Supplies · Healthcare

Life science tools demand is tied to pharma/biotech R&D budgets; GLP-1 clinical development is a current bright spot driving CRO and instrument demand. Academic and government research funding is the more volatile demand component.

What this means for $MDLN

Partial — upstream oil & gas exposure ties to commodity price cycle; Medline Inc.

Industry benchmark

10-name peer basket
+21.1%YTD
+26.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
28.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
5.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
7.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
5.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
6.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
24.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$0.50$0.35+41.9%
Q1 2026May 6, 2026$0.33$0.30+11.8%
Q4 2025Feb 25, 2026$0.22$0.24-5.6%
Q3 2025Nov 4, 2025$0.31——
Next earningsWed, Nov 4·consensus EPS $0.34

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$7.4B+10.7%22.6%5.7%$0.16$316.0M
Q4 FY25$7.8B+21.9%24.6%5.5%$0.22$571.0M
Q3 FY25$7.1B+15.0%23.9%8.1%$0.41$535.0M
Q2 FY25$6.9B—25.1%9.1%$0.42$103.0M

Forward consensus

5-year forecast · up to 18 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$31.1B$31.0B – $31.2B$1.51$1.45 – $1.5618
FY27$33.6B$33.4B – $33.7B$1.66$1.59 – $1.7018
FY28$36.1B$35.7B – $37.1B$1.86$1.65 – $2.0916
FY29$38.7B$38.0B – $49.6B$2.11$2.06 – $2.8815
FY30$41.3B$40.5B – $53.0B$2.37$2.31 – $3.2415

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-6.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 540.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 28Bcp 8 Holdings Mozart Manager L.l.c.10% owner33.3M sh$1.2BSellMar 10Carlyle Group Inc.10% owner26.1M sh$1.1BSellMar 10Bcp 8 Holdings Mozart Manager L.l.c.10% owner27.9M sh$1.1B
+ 13 other (8 others · 5 conversions) in window

See when $MDLN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJul 98-K — Item 5.02: Officer or director change
AI summary

Modine Manufacturing announced that Chief Operating Officer Stephen Miller will retire on August 30, 2026, citing health reasons. Miller has been a key figure in the company's transformation toward data center thermal management and Climate Solutions. His planned departure will require Modine to identify a successor or redistribute his responsibilities among the existing leadership team. The retirement was characterized as planned and health-related rather than related to any disagreement with management or board direction.

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
AI summary

Medline Inc. held its 2026 Annual Meeting on June 11, 2026. Shareholders voted on: (i) election of 12 director nominees; (ii) Say-on-Pay on an advisory basis; (iii) frequency of future Say-on-Pay advisory votes; and (iv) ratification of Ernst & Young LLP as auditor for fiscal 2026. The Say-on-Pay frequency vote is notable as a first-time disclosure for this recently-listed PE-backed medical supply company, reflecting standard public company compliance.

8-KMaterial agreementJun 28-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 8.01: Other event
AI summary

Medline's indirect subsidiaries issued $2.0B in new senior secured notes on May 28, 2026: $1.25B at 5.000% due 2031 and $750M at 5.250% due 2033, with Wilmington Trust as trustee and subsidiary guarantors. Material refinancing of Medline's private-company debt stack at fixed rates, locking in long-term financing.

424B4Prospectus supplement (offering)May 26424B4
AI summary

Selling stockholders of Medline Inc. (MDLN) offered 72,554,594 shares of Class A common stock at $37.00/share ($2.685 billion gross); Medline receives no proceeds from this secondary offering. Underwriting discounts are $0.4625/share; selling stockholders net ~$36.54/share (~$2.651B). Underwriters hold an overallotment option for 10,883,189 additional shares; delivery expected May 28, 2026. Lead underwriters include Goldman Sachs, Morgan Stanley, BofA, and JPMorgan. This is a large secondary sale with no new company dilution.

S-1Initial registrationMay 20S-1
AI summary

Medline Inc. (MDLN) filed an S-1 registration statement on May 20, 2026, initiating the registration process for an initial public offering. Medline is a Northfield, Illinois-based private healthcare supply company — one of the largest private companies in the U.S. — with CEO James Boyle. The S-1 filing marks the beginning of Medline's path to a public listing; the company had previously been taken private by a private equity consortium in 2021 for approximately $34 billion. This is a potentially large and transformative IPO for the healthcare supplies sector.

3New insider — initial holdingsMar 63
424B4Prospectus supplement (offering)Mar 6424B4
+ 20 other (7 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 EFFECTs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Kaplan Fox Encourages Investors of Medline Inc. (MDLN) Who Suffered Losses to Contact the Firm Regarding a Securities Investigationnewsfilecorp.com·3d agoKaplan Fox Alerts Medline Inc. (MDLN) Investors to an Investigation of Potential Securities Law Violationsnewsfilecorp.com·5d agoKaplan Fox Announces a Securities Investigation into Medline Inc. (MDLN) - Investors Encouraged to Contact the Firmnewsfilecorp.com·7d agoKaplan Fox Encourages Investors of Medline Inc. (MDLN) to Contact the Firm to Learn About Their Legal Rightsnewsfilecorp.com·9d agoMDLN INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firmglobenewswire.com·10d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Medical - Instruments & Supplies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BDX$ISRG$AVTR$QDEL$RGEN$WST$PLSE$BLFS
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport